A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

NCT06221969 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1024

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Tirzepatide

Sponsor

Novo Nordisk A/S